… The primary objective of this study was to characterize the pharmacokinetics of erlotinib in
a large number of patients with solid tumors and identify covariates that have an impact on its …

… The safety profile of erlotinib in this study was as expected… study received treatment with
erlotinib for a longer duration than patients treated in the second- and third-line Japanese studies…

… of elevated Src activity in human lung cancers, we conducted a phase I trial of combined
erlotinib and dasatinib in patients with advanced non–small-cell lung cancer (NSCLC). The …

… non-small cell lung cancer (NSCLC). Based on the results of two multicenter phase II studies
[1… Our search yielded a total of 496 potentially relevant studies with gefitinib or erlotinib. The …

… The purpose of this study was to assess efficacies of erlotinib and gefitinib in the management
of LMC from NSCLC by comparing the cytologic negative conversion rates of the CSF in …

… Recently, randomised, placebo-controlled, Phase III data for gefitinib from the ISEL (Iressa
Survival Evaluation in Lung cancer) study, that investigated treatment with gefitinib compared …

… Erlotinib is registered for treatment of all patients with advanced non-small-cell lung cancer
(… Three studies have described activating mutations in advanced NSCLC that made tumours …

… The phase III IUNO trial assessed the benefit of maintenance erlotinib versus erlotinib at
progression in advanced/metastatic non-small-cell lung cancer (NSCLC) that had not …

… non–small-cell lung cancer (NSCLC). We hypothesized that erlotinib would be efficacious in
… In conclusion, this study did not show a DFS benefit for erlotinib in patients with IHC- or FISH…

… -cell lung cancer (NSCLC) is among the epithelial cancers that … This study showed that
erlotinib significantly prolonged survival … lung cancer symptoms, showed that patients receiving …